Elizabeth Miller

Summary

Affiliation: Central Public Health Laboratory
Country: UK

Publications

  1. ncbi Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40
    Wendy A Knowles
    Enteric, Respiratory and Neurological Virus Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency, Colindale, London, United Kingdom
    J Med Virol 71:115-23. 2003
  2. ncbi Immunogenicity and reactogenicity of acellular diphtheria/tetanus/pertussis vaccines given as a pre-school booster: effect of simultaneous administration of MMR
    E Miller
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 19:3904-11. 2001
  3. ncbi Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
    E Miller
    Immunisation Division, Public Health Laboratory Service, Communicable Disease Surveillance Centre, 61 Colindale Avenue, NW9 5EQ, London, UK
    Vaccine 20:S58-67. 2001
  4. ncbi MMR vaccine: review of benefits and risks
    E Miller
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London, UK
    J Infect 44:1-6. 2002
  5. ncbi Measles-mumps-rubella vaccine and the development of autism
    Elizabeth Miller
    Immunisation Division, Public Health Laboratory Service, 61 Colindale Avenue, London NW9 5EQ, UK
    Semin Pediatr Infect Dis 14:199-206. 2003
  6. pmc Bacterial infections, immune overload, and MMR vaccine. Measles, mumps, and rubella
    E Miller
    Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, 61 Colindale Avenue, London NW9 5EQ, UK
    Arch Dis Child 88:222-3. 2003
  7. pmc Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales
    Shamez N Ladhani
    Immunisation Department, Health Protection Agency Colindale, London, UK
    Emerg Infect Dis 19:61-8. 2013
  8. ncbi Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
    Caroline L Trotter
    Statistics, Economics, and Modelling Department, Health Protection Agency Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Lancet 364:365-7. 2004
  9. ncbi Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations
    Jo Southern
    Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, UK
    Hum Vaccin 2:237-42. 2006
  10. pmc Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity
    Helen Campbell
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Clin Vaccine Immunol 17:840-7. 2010

Detail Information

Publications80

  1. ncbi Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40
    Wendy A Knowles
    Enteric, Respiratory and Neurological Virus Laboratory, Specialist and Reference Microbiology Division, Health Protection Agency, Colindale, London, United Kingdom
    J Med Virol 71:115-23. 2003
    ..There is no serological evidence that SV40 entered the human population during the past 80 years, and the possibility of cross-reaction with BKV or JCV antibody must be considered...
  2. ncbi Immunogenicity and reactogenicity of acellular diphtheria/tetanus/pertussis vaccines given as a pre-school booster: effect of simultaneous administration of MMR
    E Miller
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 19:3904-11. 2001
    ....
  3. ncbi Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
    E Miller
    Immunisation Division, Public Health Laboratory Service, Communicable Disease Surveillance Centre, 61 Colindale Avenue, NW9 5EQ, London, UK
    Vaccine 20:S58-67. 2001
    ..Surveillance of the prevalent serogroups and serosubtypes among invasive case isolates has shown no evidence of any capsular switching to serogroup B during the first 18 months of the MCC vaccination programme...
  4. ncbi MMR vaccine: review of benefits and risks
    E Miller
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London, UK
    J Infect 44:1-6. 2002
  5. ncbi Measles-mumps-rubella vaccine and the development of autism
    Elizabeth Miller
    Immunisation Division, Public Health Laboratory Service, 61 Colindale Avenue, London NW9 5EQ, UK
    Semin Pediatr Infect Dis 14:199-206. 2003
    ..No epidemiologic evidence suggests an association between MMR vaccination and autism. Moreover, epidemiologic evidence against such an association is compelling...
  6. pmc Bacterial infections, immune overload, and MMR vaccine. Measles, mumps, and rubella
    E Miller
    Immunisation Division, Communicable Disease Surveillance Centre, Public Health Laboratory Service, 61 Colindale Avenue, London NW9 5EQ, UK
    Arch Dis Child 88:222-3. 2003
    ..These results provide no support for the concept of "immunological overload" induced by multiple antigen vaccinations, nor calls for single antigen vaccines...
  7. pmc Invasive pneumococcal disease after routine pneumococcal conjugate vaccination in children, England and Wales
    Shamez N Ladhani
    Immunisation Department, Health Protection Agency Colindale, London, UK
    Emerg Infect Dis 19:61-8. 2013
    ..4% (58/1,332) but higher for meningitis (11.0%) and children with comorbidities (9.1%). Thus, comorbidities were more prevalent in children with IPD caused by non-PCV13 serotypes and were associated with increased case fatality...
  8. ncbi Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
    Caroline L Trotter
    Statistics, Economics, and Modelling Department, Health Protection Agency Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Lancet 364:365-7. 2004
    ..The number of individuals in these cohorts remains low, but alternative routine immunisation schedules should be considered to ensure high levels of protection are sustained...
  9. ncbi Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, or a month prior to or after, tetanus and diphtheria booster vaccinations
    Jo Southern
    Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London, UK
    Hum Vaccin 2:237-42. 2006
    ..This single blind study was conducted to address safety concerns regarding coadministration of diphtheria/ tetanus (DT,Td) boosters and meningococcal C conjugate (MCC) vaccines containing diphtheria or tetanus conjugate proteins...
  10. pmc Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity
    Helen Campbell
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Clin Vaccine Immunol 17:840-7. 2010
    ..Modeling suggested that protection against carriage persists for at least 3 years and predicted the stabilization of serogroup C disease at low levels (fewer than 50 cases per year) up to 2015-2016...
  11. pmc Seroprevalence of influenza A(H1N1)pdm09 virus antibody, England, 2010 and 2011
    Katja Hoschler
    Respiratory Virus Unit, Virus Reference Department, Microbiology Services Colindale, Health Protection Agency, 61 Colindale Ave, London, NW9 5HT, UK
    Emerg Infect Dis 18:1894-7. 2012
    ..Population-based seroepidemiology confirms that the third wave of influenza A(H1N1)pdm09 virus circulation was associated with a shift in age groups affected, with the highest rate of infection in young adults...
  12. doi Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 29:9127-31. 2011
    ..VE for serotypes 1 and 3 was 62% and 66% respectively although confidence intervals spanned zero. IPD due to PCV13-only serotypes halved in children under 2 years in the study period...
  13. pmc Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults
    Jo Southern
    Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Ave, Colindale, London, United Kingdom
    Clin Diagn Lab Immunol 11:1100-4. 2004
    ..The study shows that MCC-TT is safe and immunogenic in naive and previously MACP-vaccinated adults, though the magnitude and persistence of postvaccination SBA responses in the latter group were lower...
  14. pmc The impact of specific and non-specific immunity on the ecology of Streptococcus pneumoniae and the implications for vaccination
    Stefan Flasche
    Immunisation, Hepatitis and Blood Safety Department, Public Health England, 61 Colindale Avenue, Colindale, London NW9 5EQ, UK, Department of Mathematics and Statistics, Strathclyde University, 26 Richmond Street, Glasgow G1 1XH, UK, Centre for the Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK, Health Protection Scotland, 5 Cadogan Street, Glasgow G2 6QE, UK, International Prevention Research Institute, 95 cours Lafayette, Lyon 69006, France
    Proc Biol Sci 280:20131939. 2013
    ..Hence, if vaccine effects are insufficient to control the majority of serotypes at the same time, then exploiting the competitive pressure by selective vaccination can help control the most pathogenic serotypes. ..
  15. doi The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England
    Albert Jan van Hoek
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    J Infect 65:17-24. 2012
    ..Three years of post 7-valent pneumococcal conjugate vaccine (PCV7) data was included to investigate the herd protection effects...
  16. pmc Accelerating control of pertussis in England and Wales
    Helen Campbell
    Health Protection Agency, London, UK
    Emerg Infect Dis 18:38-47. 2012
    ..e., <3 months of age), teenagers, and adults. Future vaccine program changes may be beneficial, but additional detail is required to inform such decisions...
  17. ncbi Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales
    Caroline L Trotter
    Immunisation Department, Health Protection Agency Centre for Infections, London, UK
    Hum Vaccin 2:68-73. 2006
    ..The inclusion of a booster dose is likely to improve the impact of the MCC program and reducing the number of doses in infancy will improve cost-effectiveness and create space in the schedule for the addition of other vaccines...
  18. doi No evidence of an increase of bacterial and viral infections following Measles, Mumps and Rubella vaccine
    Julia Stowe
    Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 27:1422-5. 2009
    ....
  19. ncbi Role of PCR in the diagnosis of pertussis infection in infants: 5 years' experience of provision of a same-day real-time PCR service in England and Wales from 2002 to 2007
    Norman K Fry
    Respiratory and Systemic Infection Laboratory, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London, UK
    J Med Microbiol 58:1023-9. 2009
    ..Real-time PCR is an invaluable tool both for enhanced epidemiological surveillance and for the provision of a rapid diagnosis of pertussis where results can affect patient and contact management...
  20. doi Meningococcal C conjugate vaccine: the experience in England and Wales
    Helen Campbell
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 27:B20-9. 2009
    ..The MCC immunization programme has been extremely successful in controlling serogroup C disease and continues to be evaluated. The aim of this paper is to review the experiences in England and Wales over the past 9 years...
  21. doi Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database
    Julia Stowe
    Immunisation Department, Health Protection Agency Centre for Infections, London, UK
    Am J Epidemiol 169:382-8. 2009
    ....
  22. pmc Validity of a reported history of chickenpox in targeting varicella vaccination at susceptible adolescents in England
    Nigel Field
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Health Protection Agency, 61 Colindale Avenue, London NW9 5EQ, United Kingdom 1 Research Department of Infection and Population Health, University College London, Mortimer Market Centre, off Capper Street, London WC1E 6JB, United Kingdom Electronic address
    Vaccine 32:1213-7. 2014
    ..To inform this approach, we estimated the proportion of adolescents with varicella antibodies by reported chickenpox history...
  23. doi Invasive pneumococcal disease among HIV-positive individuals, 2000-2009
    Zheng Yin
    HIVand STI Department, Health Protection Agency, London, UK
    AIDS 26:87-94. 2012
    ....
  24. doi No effect of 2008/09 seasonal influenza vaccination on the risk of pandemic H1N1 2009 influenza infection in England
    Richard Pebody
    Health Protection Agency Centre for Infections, 61 Colindale Avenue, UK
    Vaccine 29:2613-8. 2011
    ..Vaccine effectiveness did not differ significantly by age-group or hospitalisation status. There was no evidence prior vaccination with TIV significantly altered subsequent risk of pandemic influenza H1N1 2009 infection...
  25. doi The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England
    Albert Jan van Hoek
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Services, Colindale, Health Protection Agency, London NW9 5EQ, UK
    Vaccine 30:7205-13. 2012
    ....
  26. pmc No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome
    Brent Taylor
    General and Adolescent Paediatric Unit, Institute of Child Health, University College London, London, UK
    Arch Dis Child 92:887-9. 2007
    ..To investigate whether meningococcal C conjugate vaccine (MCCV) caused relapse in children with steroid-responsive nephrotic syndrome...
  27. ncbi Post-licensure safety of the meningococcal group C conjugate vaccine
    Nick Andrews
    Statistics Unit, Health Protection Agency, Centre for Infections, London, UK
    Hum Vaccin 3:59-63. 2007
    ..15 (0.80-1.67). There was evidence of an increased risk of convulsions and idiopathic thrombocytopenic purpura following MMR vaccination as previously documented...
  28. ncbi Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England
    Alan P Johnson
    Department of Healthcare Associated Infection and Antimicrobial Resistance, Health Protection Agency Centre for Infections, London, NW9 5EQ, UK
    J Infect 55:394-9. 2007
    ....
  29. ncbi Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London, UK
    Lancet Infect Dis 11:760-8. 2011
    ..We assess the effect of the PCV7 vaccination on VT and NVT disease in England and Wales...
  30. ncbi Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers
    Jo Southern
    Immunisation Department, Communicable Disease Surveillance Centre, Health Protection Agency, 61 Colindale Avenue, Colindale, London, UK
    Vaccine 23:3829-35. 2005
    ....
  31. pmc Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study
    Marc Baguelin
    Immunisation, Hepatitis and Blood Safety Department, Public Health England, London, United Kingdom Centre for the Mathematical Modelling of Infectious Diseases, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS Med 10:e1001527. 2013
    ..We developed methods to synthesise the multiplicity of surveillance datasets in order to evaluate how changing target populations in the seasonal vaccination programme would affect infection rate and mortality...
  32. ncbi Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London NW9 5EQ, UK
    BMJ 346:f794. 2013
    ..To evaluate the risk of narcolepsy in children and adolescents in England targeted for vaccination with ASO3 adjuvanted pandemic A/H1N1 2009 vaccine (Pandemrix) from October 2009...
  33. doi Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines
    Nick J Andrews
    Department of Statistics, Modelling and Economics, Health Protection Services, Health Protection Agency, Colindale, London NW9 5EQ, UK
    Vaccine 29:7913-9. 2011
    ..Reduction in the interval between doses for earlier protection would be at the cost of reduced immunogenicity. The effect of seasonal vaccine on immunogenicity merits further investigation...
  34. ncbi Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association
    Nick Andrews
    Statistics Unit, Health Protection Agency, Communicable Disease Surveillance Centre, London, United Kingdom
    Pediatrics 114:584-91. 2004
    ....
  35. ncbi Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study
    Elizabeth Miller
    Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency Centre for Infections, London, UK
    Lancet 375:1100-8. 2010
    ....
  36. ncbi Sero-epidemiological patterns of Epstein-Barr and herpes simplex (HSV-1 and HSV-2) viruses in England and Wales
    Marianne C Morris
    Immunisation Division, Communicable Disease Surveillance Centre, London, United Kingdom
    J Med Virol 67:522-7. 2002
    ..Continuing surveillance of these herpes viruses is necessary as the predicted changes could have a significant public health impact, especially in the young adult population...
  37. ncbi Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era
    Caroline Trotter
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, 61 Colindale Avenue, London NW9 5EQ, UK
    Vaccine 21:1094-8. 2003
    ..This study provides baseline antibody levels which will facilitate the evaluation of the meningococcal serogroup C conjugate vaccination programme...
  38. ncbi Natural and vaccine-induced immunity and immunologic memory to Neisseria meningitidis serogroup C in young adults
    David Goldblatt
    Immunobiology Unit, Institute of Child Health, Public Health Laboratory Service, Communicable Disease Surveillance Centre, London, United Kingdom
    J Infect Dis 185:397-400. 2002
    ....
  39. ncbi Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom
    Ray Borrow
    Public Health Laboratory Service Meningococcal Reference Unit, Withington Hospital, Manchester, United Kingdom
    J Infect Dis 186:1353-7. 2002
    ..6; 95% CI, 338.0-2568.1). This is the first demonstration of immunological memory at 4 years of age in children receiving MCC vaccine on the United Kingdom's 2/3/4-month immunization schedule...
  40. doi Post-licensure comparison of the safety profile of diphtheria/tetanus/whole cell pertussis/haemophilus influenza type b vaccine and a 5-in-1 diphtheria/tetanus/acellular pertussis/haemophilus influenza type b/polio vaccine in the United Kingdom
    Nick Andrews
    Statistics Unit, Health Protection Agency, Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom
    Vaccine 28:7215-20. 2010
    ..Although there were no other significant differences between vaccines the relative incidence was significantly above one on the day of vaccination for convulsions following DTwP/Hib and for apnoea/collapse following DTaP(5)/Hib/IPV...
  41. pmc Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
    Nick Andrews
    Immunisation Division, PHLS Communicable Disease Surveillance Centre, London NW9 5EQ, United Kingdom
    Clin Diagn Lab Immunol 10:780-6. 2003
    ....
  42. pmc Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis
    Mary E Ramsay
    Public Health Laboratory Service Communicable Disease Surveillance Centre, London, NW9 5EQ
    BMJ 326:365-6. 2003
  43. ncbi Bell's palsy and parenteral inactivated influenza vaccine
    Julia Stowe
    Immunisation Department, Health Protection Agency Centre for Infections, London, UK
    Hum Vaccin 2:110-2. 2006
    ..78-1.08). There was also no evidence of an increased risk in any age group or following pneumococcal vaccine. A significant increase was seen on the day of vaccination (day 0) probably due to opportunistic recording of cases...
  44. ncbi New estimates of herpes simplex virus type 2 seroprevalence in England: 'high' but stable seroprevalence over the last decade
    Marianne Morris-Cunnington
    Immunisation Division, Communicable Disease Surveillance Centre, London, UK
    Sex Transm Dis 31:243-6. 2004
    ..This study aimed to ascertain trends in HSV-2 infection in England between 1991 and 2000...
  45. ncbi Laboratory diagnosis of pertussis infections: the role of PCR and serology
    Norman K Fry
    Respiratory and Systemic Infection Laboratory and Special Projects Laboratory, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
    J Med Microbiol 53:519-25. 2004
    ..Rapid diagnosis of B. pertussis infection particularly in infants by PCR, together with serological assays, can enhance surveillance systems for pertussis in all age groups...
  46. pmc Effect of vaccination with carrier protein on response to meningococcal C conjugate vaccines and value of different immunoassays as predictors of protection
    Moya Burrage
    Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire, United Kingdom
    Infect Immun 70:4946-54. 2002
    ....
  47. pmc Serotype-specific immune unresponsiveness to pneumococcal conjugate vaccine following invasive pneumococcal disease
    Ray Borrow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester M13 9XZ, United Kingdom
    Infect Immun 76:5305-9. 2008
    ..This serotype-specific unresponsiveness may reflect immune paralysis due to large pneumococcal polysaccharide antigen loads and/or a potential genetic basis for nonresponse to individual pneumococcal serotypes...
  48. pmc Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom
    Ray Borrow
    PHLS Meningococcal Reference Unit, Withington Hospital, Manchester, United Kingdom
    Infect Immun 71:5549-55. 2003
    ..This study provides the first evidence that the number of doses of MCC-TT used in infant immunization schedules could be decreased...
  49. ncbi Meningococcal disease: how to prevent and how to manage
    Paul Balmer
    Vaccine Evaluation Department, Manchester Public Health Laboratory Service, Withington Hospital, Manchester, UK
    Curr Opin Infect Dis 15:275-81. 2002
    ..The aim of this review is to highlight recent significant improvements in the prevention and management of meningococcal disease...
  50. pmc Immunogenicity of a fourth dose of Haemophilus influenzae type b (Hib) conjugate vaccine and antibody persistence in young children from the United Kingdom who were primed with acellular or whole-cell pertussis component-containing Hib combinations in inf
    Jo Southern
    Immunisation Department, Centre for Infections, Health Protection Agency, London NW9 5EQ, United Kingdom
    Clin Vaccine Immunol 14:1328-33. 2007
    ..15 microg/ml in about 90% of individuals. A booster dose of Hib vaccine given after the first year of life should provide long-lasting protection...
  51. pmc Measles, mumps, and rubella vaccination and bowel problems or developmental regression in children with autism: population study
    Brent Taylor
    Centre for Community Child Health, Royal Free and University College Medical School, University College London Royal Free Campus, London
    BMJ 324:393-6. 2002
    ..To investigate whether measles, mumps, and rubella (MMR) vaccination is associated with bowel problems and developmental regression in children with autism, looking for evidence of a "new variant" form of autism...
  52. pmc Deaths from chickenpox. Deaths from chickenpox in adults are decreasing
    Marc Brisson
    BMJ 324:609. 2002
  53. ncbi Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers
    David Goldblatt
    Institute of Child Health, University College London, UK
    Pediatr Infect Dis J 25:312-9. 2006
    ..The minimum number of doses of pneumococcal conjugate vaccine required for protection is not known. We studied the immunogenicity of a reduced schedule in infants and toddlers...
  54. ncbi Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants
    Emma Longworth
    Meningococcal Reference Unit, Manchester Public Health Laboratory, Withington Hospital, Nell Lane, UK
    Vaccine 20:2592-6. 2002
    ..No increase in avidity was observed in the control group. Antibody avidity indices are useful laboratory markers for the priming of immunological memory following vaccination with meningococcal serogroup B OMV vaccines...
  55. pmc Increasing hospital admissions for pneumonia, England
    Caroline L Trotter
    University of Bristol, Bristol, UK
    Emerg Infect Dis 14:727-33. 2008
    ..It may be attributable to other population factors, changes in HES coding, changes to health service organization, other biologic phenomenon, or a combination of these effects...
  56. pmc Comparison of rubella seroepidemiology in 17 countries: progress towards international disease control targets
    Anthony Nardone
    Centre for Infections, Health Protection Agency, London, England
    Bull World Health Organ 86:118-25. 2008
    ..To standardize serological surveillance to compare rubella susceptibility in Australia and 16 European countries, and measure progress towards international disease-control targets...
  57. ncbi Long-term protection in children with meningococcal C conjugate vaccination: lessons learned
    Ray Borrow
    Vaccine Evaluation Unit, NW Regional HPA Laboratory, Manchester Medical Microbiology Partnership, PO Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, M13 9WZ, UK
    Expert Rev Vaccines 5:851-7. 2006
    ..The assumption that immune memory was predictive of long-term protection is incorrect, at least after vaccination in infancy. Persistence of antibody and herd immunity may be more relevant for long-term disease control...
  58. ncbi Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom
    Cressida Auckland
    Immunisation Department, Centre for Infections, Health Protection Agency, Manchester Royal Infirmary, Manchester, United Kingdom
    J Infect Dis 194:1745-52. 2006
    ..The meningococcal serogroup C conjugate (MCC) vaccine was introduced into the United Kingdom with licensure based on immunogenicity data not efficacy data...
  59. ncbi Meningococcal surrogates of protection--serum bactericidal antibody activity
    Ray Borrow
    Meningococcal Reference Unit, Health Protection Agency North West Laboratory, Manchester Royal Infirmary, Manchester M13 9WZ, UK
    Vaccine 23:2222-7. 2005
    ..SBA activity as a correlate of protection for evaluating the immune response to meningococcal vaccines is described in this review...
  60. pmc Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac
    Jamie Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, Manchester Laboratory, Manchester Medical Microbiology Partnership, Manchester Royal Infirmary, Manchester, United Kingdom
    Infect Immun 74:4557-65. 2006
    ..These results emphasize the need for standardized methodologies that would allow a more robust comparison of assays between laboratories and promote their further evaluation as correlates of protection against MenB disease...
  61. pmc Seroprevalence of bactericidal and anti-outer membrane vesicle antibodies to Neisseria meningitidis group B in England
    Caroline Trotter
    Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol BS8 2PR, United Kingdom
    Clin Vaccine Immunol 14:863-8. 2007
    ..With the exception of children aged 3 to 11 months, there was no clear relationship between disease incidence and seroprevalence...
  62. pmc Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine
    Helen Findlow
    Vaccine Evaluation Unit, Health Protection Agency North West, P O Box 209, Clinical Sciences Building, Manchester Royal Infirmary, Manchester, M13 9WZ, United Kingdom
    Clin Vaccine Immunol 13:507-10. 2006
    ..Further studies on IgG subclasses following meningococcal polysaccharide and conjugate vaccination are needed...
  63. pmc Age-stratified prevalences of pneumococcal-serotype-specific immunoglobulin G in England and their relationship to the serotype-specific incidence of invasive pneumococcal disease prior to the introduction of the pneumococcal 7-valent conjugate vaccine
    Paul Balmer
    Vaccine Evaluation Unit, Health Protection Agency, Manchester Laboratory, Clinical Sciences Building 2, Manchester Royal Infirmary, Oxford Road, Manchester, United Kingdom M13 9WZ
    Clin Vaccine Immunol 14:1442-50. 2007
    ..These data provide a baseline for natural immunity to the pneumococcal serotypes analyzed prior to the introduction of pneumococcal conjugate vaccine in the United Kingdom...
  64. ncbi Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniae in adults: a longitudinal household study
    David Goldblatt
    Immunobiology Unit, Institute of Child Health, University College London, UK
    J Infect Dis 192:387-93. 2005
    ..pneumoniae or cross-reactive antigens. No longitudinal studies of carriage of and immune responses to S. pneumoniae have been conducted using sophisticated immunological laboratory techniques...
  65. ncbi Varicella vaccine and shingles
    Marc Brisson
    JAMA 287:2211; author reply 2211-2. 2002
  66. ncbi A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococc
    Nicholas Kitchin
    Sanofi Pasteur MSD Ltd, Mallards Reach, Bridge Avenue, Maidenhead, Berkshire SL6 1QP, UK
    Vaccine 24:3964-70. 2006
    ..The pentavalent DTaP-IPV-Hib vaccine was less reactogenic than the quadrivalent DTwP-Hib vaccine, as expected when changing from whole cell pertussis (wP) to an acellular pertussis (aP) component...
  67. ncbi Pneumococcal polysaccharide vaccine uptake in England, 1989-2003, prior to the introduction of a vaccination programme for older adults
    Karen Noakes
    Immunisation Policy, Monitoring and Surveillance, Department of Health, Wellington House, 133 155 Waterloo Road, London SE1 8UG, UK
    J Public Health (Oxf) 28:242-7. 2006
    ..In England, this was phased in over 3 years. To ascertain the performance of the risk group policy in those 65 years of age and over and provide a baseline to estimate the impact of the universal elderly programme...
  68. ncbi Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study
    Elinor Reynolds
    National Institute for Biological Standards and Control, Division of Bacteriology, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG, UK
    Vaccine 24:3248-57. 2006
    ..Protection against aerosol challenge with virulent Bordetella pertussis was related to the magnitude of the antibody and CMI responses in the mouse model. As in the human subjects, the responses remained skewed towards Th1 type...
  69. ncbi Susceptibility of pneumococci causing meningitis in England and Wales to first-line antimicrobial agents, 2001-2004
    Alan P Johnson
    J Antimicrob Chemother 56:1181-2. 2005
  70. ncbi Idiopathic thrombocytopenic purpura and the second dose of MMR
    Julia Stowe
    Arch Dis Child 93:182-3. 2008
  71. ncbi Upper respiratory tract carriage and transmission of pneumococci
    Mahein Hussain
    Institute of Child Health, London
    Nurs Times 100:36-9. 2004
    ..This article looks at the possible introduction of a new pneumococcal conjugate vaccine and reviews a longitudinal carriage study of pneumococcus in UK families to determine pneumococcal carriage rates...
  72. doi Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study
    Seung Hyuk Choi
    Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Am Coll Cardiol 52:24-32. 2008
    ..This study was designed to test the hypothesis that circulating biomarkers of oxidized low-density lipoprotein (OxLDL) are affected by statin therapy and predict changes in atheroma volume...
  73. doi Meningococcal C booster not recommended by evidence
    H Lucy Thomas
    BMJ 337:a1139. 2008
  74. ncbi Male partner pregnancy-promoting behaviors and adolescent partner violence: findings from a qualitative study with adolescent females
    Elizabeth Miller
    Center for Reducing Health Disparities, UC Davis School of Medicine, Sacramento, CA 95817, USA
    Ambul Pediatr 7:360-6. 2007
    ..This paper reports on a subset of females who described abusive male partners' explicit pregnancy-promoting behaviors (ie, messages and behaviors that led females to believe their partner was actively trying to impregnate them)...
  75. pmc Canadian economic evaluation of budesonide-formoterol as maintenance and reliever treatment in patients with moderate to severe asthma
    Elizabeth Miller
    Axia Research Inc, 181 Main Street West, Hamilton, Ontario, Canada
    Can Respir J 14:269-75. 2007
    ....
  76. ncbi Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines
    Thomas Verstraeten
    GlaxoSmithKline Biologicals, Rixensart, Belgium
    Expert Rev Vaccines 2:21-9. 2003
    ..We also offer our opinion on the future use of large linked databases for vaccine safety surveillance purposes...
  77. ncbi Risk of serious neurologic disease after immunization of young children in Britain and Ireland
    Katherine N Ward
    Centre for Virology UCL Campus, Division of Infection and Immunity, Royal Free and University College Medical School, Windeyer Institute of Medical Sciences, 46 Cleveland St, London W1T 4JF, United Kingdom
    Pediatrics 120:314-21. 2007
    ..We sought to investigate the risk of serious neurologic disease after immunization in early childhood...
  78. ncbi Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a)
    Celina Edelstein
    Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
    J Biol Chem 278:52841-7. 2003
    ....
  79. ncbi Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes
    Sotirios Tsimikas
    Department of Medicine, University of California at San Diego, 9500 Gilman Drive, BSB 1080, La Jolla, CA 92093 0682, USA
    J Am Coll Cardiol 41:360-70. 2003
    ..This study was conducted to test the hypothesis that plasma markers of oxidized low-density lipoprotein (OxLDL) reflect acute coronary syndromes (ACS)...
  80. ncbi Informed choice, balance, and the MMR-autism saga
    C Paddy Farrington
    Department of Statistics, The Open University, Milton Keynes, UK
    Lancet Infect Dis 5:2-3; discussion 3-4. 2005